{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T21:35:43Z","timestamp":1787175343970,"version":"build-2736575974"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,25]],"date-time":"2023-01-25T00:00:00Z","timestamp":1674604800000},"content-version":"vor","delay-in-days":116,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.msard.2022.104034","type":"journal-article","created":{"date-parts":[[2022,7,5]],"date-time":"2022-07-05T01:46:31Z","timestamp":1656985591000},"page":"104034","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Evaluation of functional outcome measures after fampridine treatment in patients with multiple sclerosis - An interventional follow-up study"],"prefix":"10.1016","volume":"66","author":[{"given":"Cecilie Dollerup","family":"Skov","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina Borgen","family":"S\u00f8rensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Thorning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate Lykke","family":"Lambertsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars Henrik","family":"Frich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik Boye","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"Holsgaard-Larsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7319-1368","authenticated-orcid":false,"given":"Helle H","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.msard.2022.104034_bib0001","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1002\/1531-8249(200006)47:6<707::AID-ANA3>3.0.CO;2-Q","article-title":"Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination","volume":"47","author":"Lucchinetti","year":"2000","journal-title":"Ann. Neurol."},{"issue":"3","key":"10.1016\/j.msard.2022.104034_bib0002","doi-asserted-by":"crossref","first-page":"189","DOI":"10.2165\/11591150-000000000-00000","article-title":"Impact of walking impairment in multiple sclerosis: perspectives of patients and care partners","volume":"4","author":"Larocca","year":"2011","journal-title":"Patient"},{"issue":"3","key":"10.1016\/j.msard.2022.104034_bib0003","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s40263-017-0412-5","article-title":"Outcome measures in clinical trials for multiple sclerosis","volume":"31","author":"van Munster","year":"2017","journal-title":"CNS Drugs"},{"issue":"10","key":"10.1016\/j.msard.2022.104034_bib0004","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1177\/1352458517720043","article-title":"Fampridine response in MS patients with gait impairment in a real-world setting: need for new response criteria?","volume":"24","author":"Rodriguez-Leal","year":"2018","journal-title":"Mult. Scler."},{"issue":"2","key":"10.1016\/j.msard.2022.104034_bib0005","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1177\/1756285613512712","article-title":"4-Aminopyridine for symptomatic treatment of multiple sclerosis: a systematic review","volume":"7","author":"Jensen","year":"2014","journal-title":"Ther. Adv. Neurol. Disord."},{"issue":"9665","key":"10.1016\/j.msard.2022.104034_bib0006","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/S0140-6736(09)60442-6","article-title":"Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial","volume":"373","author":"Goodman","year":"2009","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.msard.2022.104034_bib0007","doi-asserted-by":"crossref","first-page":"4","DOI":"10.7224\/1537-2073-13.1.4","article-title":"Evaluating walking in patients with multiple sclerosis: which assessment tools are useful in clinical practice?","volume":"13","author":"Bethoux","year":"2011","journal-title":"Int. J. MS Care"},{"issue":"4","key":"10.1016\/j.msard.2022.104034_bib0008","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1177\/1756285610374117","article-title":"Possible clinical outcome measures for clinical trials in patients with multiple sclerosis","volume":"3","author":"Goldman","year":"2010","journal-title":"Ther. Adv. Neurol. Disord."},{"issue":"Pt 5","key":"10.1016\/j.msard.2022.104034_bib0009","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1093\/brain\/123.5.1027","article-title":"Kurtzke scales revisited: the application of psychometric methods to clinical intuition","volume":"123","author":"Hobart","year":"2000","journal-title":"Brain"},{"issue":"4","key":"10.1016\/j.msard.2022.104034_bib0010","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1191\/1352458506ms1293oa","article-title":"The six spot step test: a new measurement for walking ability in multiple sclerosis","volume":"12","author":"Nieuwenhuis","year":"2006","journal-title":"Mult. Scler."},{"issue":"1","key":"10.1016\/j.msard.2022.104034_bib0011","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1212\/WNL.60.1.31","article-title":"Measuring the impact of MS on walking ability: the 12-Item MS Walking Scale (MSWS-12)","volume":"60","author":"Hobart","year":"2003","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.msard.2022.104034_bib0012","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1177\/135245859900500409","article-title":"The Multiple Sclerosis Functional Composite Measure (MSFC): an integrated approach to MS clinical outcome assessment. National MS Society Clinical Outcomes Assessment Task Force","volume":"5","author":"Fischer","year":"1999","journal-title":"Mult. Scler."},{"issue":"10","key":"10.1016\/j.msard.2022.104034_bib0013","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1177\/1352458511408475","article-title":"Comparison of the 2- and 6-minute walk test in multiple sclerosis","volume":"17","author":"Gijbels","year":"2011","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2022.104034_bib0014","unstructured":"Jensen PVRoHB. PR\u00c6PARATER TIL BEHANDLING AF MS \u2013 SYMPTOMATISK: dansk Neurologisk Selvskab; 2015 [Available from: https:\/\/neuro.dk\/wordpress\/nnbv\/praeparater-ved-symptomatisk-ms-behandling\/#overskrift6."},{"issue":"21","key":"10.1016\/j.msard.2022.104034_bib0015","doi-asserted-by":"crossref","first-page":"e1921","DOI":"10.1212\/WNL.0000000000008519","article-title":"Evaluation of multiple sclerosis disability outcome measures using pooled clinical trial data","volume":"93","author":"Goldman","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2022.104034_bib0016","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.clineuro.2015.08.023","article-title":"Short-term impact of fampridine on motor and cognitive functions, mood and quality of life among multiple sclerosis patients","volume":"139","author":"Pavsic","year":"2015","journal-title":"Clin. Neurol. Neurosurg."},{"issue":"4","key":"10.1016\/j.msard.2022.104034_bib0017","doi-asserted-by":"crossref","first-page":"158","DOI":"10.7224\/1537-2073.2017-046","article-title":"Validation of the 2-minute walk test with the 6-minute walk test and other functional measures in persons with multiple sclerosis","volume":"20","author":"Scalzitti","year":"2018","journal-title":"Int. J. MS Care"},{"issue":"14","key":"10.1016\/j.msard.2022.104034_bib0018","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1177\/1352458514533844","article-title":"Changes in cognition, arm function and lower body function after slow-release Fampridine treatment","volume":"20","author":"Jensen","year":"2014","journal-title":"Mult. Scler."},{"issue":"9596","key":"10.1016\/j.msard.2022.104034_bib0019","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"370","author":"von Elm","year":"2007","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.msard.2022.104034_bib0020","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1177\/1352458517745725","article-title":"Test-retest agreement and reliability of the Six Spot Step Test in persons with multiple sclerosis","volume":"25","author":"Callesen","year":"2019","journal-title":"Mult. Scler."},{"issue":"8","key":"10.1016\/j.msard.2022.104034_bib0021","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1212\/WNL.58.8.1294","article-title":"Quantitative functional measures in MS: what is a reliable change?","volume":"58","author":"Schwid","year":"2002","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.msard.2022.104034_bib0022","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1002\/ana.22240","article-title":"A phase 3 trial of extended release oral dalfampridine in multiple sclerosis","volume":"68","author":"Goodman","year":"2010","journal-title":"Ann. Neurol."},{"issue":"8","key":"10.1016\/j.msard.2022.104034_bib0023","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1007\/s00415-015-7797-1","article-title":"Sustained-released fampridine in multiple sclerosis: effects on gait parameters, arm function, fatigue, and quality of life","volume":"262","author":"Allart","year":"2015","journal-title":"J. Neurol."},{"issue":"13","key":"10.1016\/j.msard.2022.104034_bib0024","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1177\/1352458513483890","article-title":"The reliability, precision and clinically meaningful change of walking assessments in multiple sclerosis","volume":"19","author":"Learmonth","year":"2013","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2022.104034_bib0025","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.jns.2016.06.019","article-title":"Early effect of dalfampridine in patients with MS: a multi-instrumental approach to better investigate responsiveness","volume":"368","author":"Brambilla","year":"2016","journal-title":"J. Neurol. Sci."},{"issue":"7","key":"10.1016\/j.msard.2022.104034_bib0026","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1177\/1545968314521010","article-title":"Responsiveness and clinically meaningful improvement, according to disability level, of five walking measures after rehabilitation in multiple sclerosis: a European multicenter study","volume":"28","author":"Baert","year":"2014","journal-title":"Neurorehabil. Neural Repair"},{"issue":"1\u20132","key":"10.1016\/j.msard.2022.104034_bib0027","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.jns.2007.11.003","article-title":"Confirmation and extension of the validity of the Multiple Sclerosis Walking Scale-12 (MSWS-12)","volume":"268","author":"Motl","year":"2008","journal-title":"J. Neurol. Sci."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034822005429?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034822005429?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T09:05:15Z","timestamp":1761901515000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034822005429"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":27,"alternative-id":["S2211034822005429"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2022.104034","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of functional outcome measures after fampridine treatment in patients with multiple sclerosis - An interventional follow-up study","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2022.104034","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"104034"}}